timothy sykes logo

Stock News

NeurAxis Secures Major Health Insurance Coverages

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 12/20/2025, 11:13 am ET 12/20/2025, 11:13 am ET | 5 min 5 min read
NeurAxis Secures Major Health Insurance Coverages Thumbnail

Neuraxis Inc. stocks have been trading up by 7.64 percent, driven by increased market confidence from promising FDA clinical results.

Healthcare industry expert:

Analyst sentiment – positive

NeurAxis (NRXS) is currently positioned in a precarious state within the healthcare sector in terms of market fundamentals. With revenue standing at approximately $2.69 million, albeit a decent gross margin at 84%, the company registers negative values across critical profitability metrics, including an EBIT margin of -274% and a net income of -$2.12 million. Additionally, the company carries substantial working capital with a current ratio of 1.6, but it remains under the burden of notable debt highlighted by a total debt-to-equity ratio of 0.21. The valuation measures such as a price-to-sales ratio of 9.12 and price-to-book value of 13.45 indicate a premium valuation, one not seemingly justified by operational performance. Overall, NRXS is in a weakened financial posture, indicating a firm needing immediate strategic pivots to improve profitability and operational efficiency.

Technically, NeurAxis shows an upward price trend over recent trading sessions, with stock prices rising from $2.65 to $3.10. This upward trajectory, coupled with steady trading volume and increasing price levels, suggests a short-term bullish sentiment. However, the sudden jump to mid-$3.10s represents a key resistance level. Should NRXS break past the $3.20 resistance convincingly, bolstered by sufficient trade volume, it may present an actionable buying opportunity for traders aiming for short-term gains. For risk mitigation, stop-loss orders around the $2.88 level are advisable, where prior support exists. The dominant trend is bullish in the short term, though investors should remain cautious of the fundamental financial instability.

Catalysts for NRXS include the recent federal supply schedule contract with the Veterans Affairs and expanded medical policy coverage, potentially providing a commercial avenue to significantly increase market reach and revenue streams. These developments are noteworthy against the benchmarks of the Medical Equipment & Supplies space, positioning NRXS for potential growth. However, the firm must leverage these opportunities efficiently to convert its technological advances such as the IB-Stim into tangible financial turnarounds. The announced new insurance coverage represents access to 100 million potential lives and could drive considerable revenue increases as early as 2026, following a new Category I CPT coding. Given these factors, my outlook tilts toward cautious optimism, provided the company executes effectively on its strategic initiatives.

Candlestick Chart

Weekly Update Dec 15 – Dec 19, 2025: On Saturday, December 20, 2025 Neuraxis Inc. stock [NYSE American: NRXS] is trending up by 7.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent trading sessions, NeurAxis Inc. saw its stock price climb, showing a steady upward trend over the last few days. An analysis of NRXS’s price movement from Dec 15 to Dec 19 reveals a sharp rise from $2.65 to $3.22, underscoring growing market confidence possibly due to strategic advancements and coverage updates. The chronological stock chart indicates not only this sharp increase but also heightened trading activity that mirrors investor optimism.

The company’s profitability ratios tell an intriguing story. With significant negative margins such as an EBIT margin of -274% and a profit margin of -248.96%, the financials reflect strains yet also reveal untapped recovery potential. Despite a high price-to-sales ratio of 9.12, the recent expansion into the VA and national health insurance systems signals an upcoming phase of accelerated revenue streams that investors are keenly eyeing. The current ratio at 1.6 indicates competent short-term liquidity, boding well for managing immediate financial commitments.

More Breaking News

Financial reports portray NeurAxis as a company navigating a challenging fiscal environment yet making decisive strides toward innovation and expanded market access. With a negative operating cash flow of $-1.42M and a net income of $-2.12M, strategic contracts and insurance agreements are pivotal as the company maneuvers past substantial financial hurdles toward future profitability.

Conclusion

NeurAxis Inc. is strategically positioned to leverage recent healthcare system inclusions to its advantage. By successfully integrating its solutions into the frameworks of vast insurance networks, the company is not just securing new revenue streams but also fortifying its presence in the medical technology landscape. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” These accomplishments reflect NRXS’s resilience and adaptability amidst adversities, heightening its allure for growth-oriented trading portfolios. Looking ahead, continued focus on strategic expansions and product acceptance will likely propel NeurAxis towards sustained financial growth and market leadership.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”